ClinVar Miner

Submissions for variant NM_001142800.2(EYS):c.9277_9278dup (p.Arg3094fs)

dbSNP: rs869312188
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001387003 SCV001587474 pathogenic not provided 2020-10-14 criteria provided, single submitter clinical testing This sequence change results in a premature translational stop signal in the EYS gene (p.Arg3094Valfs*4). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 51 amino acid(s) of the EYS protein. For these reasons, this variant has been classified as Pathogenic. This variant disrupts the C-terminus of the EYS protein. Other variant(s) that disrupt this region (p.Tyr3135*) have been determined to be pathogenic (PMID: 18976725, 31074760, 29159838, 30337596). This suggests that variants that disrupt this region of the protein are likely to be causative of disease. This variant has been observed in individual(s) with retinitis pigmentosa (PMID: 22581970). ClinVar contains an entry for this variant (Variation ID: 224759). This variant is not present in population databases (ExAC no frequency).
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV003114370 SCV003800865 likely pathogenic Retinitis pigmentosa 2023-01-31 criteria provided, single submitter clinical testing Variant summary: EYS c.9277_9278dupGG (p.Arg3094ValfsX4) is located in exon 43 (i.e. in the last exon), and results in a premature termination codon that is not expected to cause nonsense mediated decay (NMD), but is predicted to cause a truncation of the encoded protein, that removes a part of the fifth laminin G domain (amino acids 2975-3165; IPR001791). Truncations downstream of this position have been reported in affected individuals (HGMD). The variant was absent in 155724 control chromosomes (gnomAD). c.9277_9278dupGG has been reported in the literature in at least one compound heterozygous individual affected with inherited retinal disease (O'Sullivan_2012, Ellingford_2016). These data do not allow any conclusion about variant significance. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic.
Centre for Genomic Medicine, Manchester, Central Manchester University Hospitals RCV000210301 SCV000259108 likely pathogenic Retinal dystrophy 2015-01-30 no assertion criteria provided clinical testing
Natera, Inc. RCV001828049 SCV002083454 pathogenic Retinitis pigmentosa 25 2020-12-07 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.